Hellmann MD, Antonia S, Ponce S, et al. Nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-year survival and updated analyses from the Checkmate 032 trial. Proc 16th World Congress on Lung Cancer (WCLC). 2016; Abstr.